에 대한 최신 뉴스 ImmunityBio (NASDAQ:IBRX) 주식

ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

Mid Cap

News

Movers

Trading Ideas

$BTC

IBRX

IONQ

IRTC

WULF

이들 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이뮤니티바이오(NASDAQ:IBRX)의 주식은 회사가 재발성 B-세포 비호지킨 림프종에 대한 CAR-NK 세포 치료제의 1상 임상 연구에서 첫 환자에게 투여했다고 발표한 후 49.86% 상승했다.

트럼프 미디어와 스트라이드는 지난주 최고 성과를 보여준 10개 중형주 중 일부 (10월 21일-10월 25일)

AMKR

BILI

BRFS

ITCI

OLLI

RKLB

TALO

이들 중형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 빌리빌리(NASDAQ:BILI)의 주가는 지난주 &#39;산구오: 무딩티엔샤(San Guo: Mou Ding Tian Xia)&#39; 발표 이후 23.32% 상승했다. 또한 JP모건 애널리스트 다니엘 첸(Daniel Chen)은 중국의 빌리빌리를 중립에서 비중확대로 상향 조정하고 21달러 가격 목표를 발표했다. 

빌리빌리와 올리즈 바겐은 지난주 최대 성과를 보인 10개 중형주 중 일부 (6월 16일-6월 22일)

ImmunityBio Inc

Looking into the current session, AECOM Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) shares are trading at $106.33, after a 0.81% decrease. Over the past month, the stock fell by 1.47%, but over the past year, it actually went up by 22.38%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1731691811_0.png" alt="Past Year Chart" />

<h3>AECOM P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 51.71 in the Construction &amp; Engineering industry, AECOM Inc. has a lower P/E ratio of 39.56. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1731691811_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for AECOM

Goldman Sachs <a href="https://www.benzinga.com/insights/analyst-ratings/24/11/42004767/breaking-down-united-airlines-holdings-11-analysts-share-their-views">has resumed coverage</a> of nine airlines and gave a broad overview of the year ahead for the airline sector. Here's a look at the winners and losers in the industry.
The Details: Goldman Sachs analyst Catherine O'Brien said the firm expects supply constraints to continue for the airlines into 2025. She sees mixed stock performance ahead, with the airlines exposed to premium and corporate demand outperforming the sector. 
Read More: <a href="https://www.benzinga.com/general/social-media/24/11/41993328/trump-media-insiders-sell-more-than-16-million-in-djt-stock">Trump Media Insiders Sell More Than $16 Million In DJT Stock</a>
ALK: The firm resumed coverage of Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) with a Buy rating and a $70 price target on the stock. The analyst pointed to the airline's exposure to the West Coast corporate travel demand, which has begun to recover significantly. 
She also noted Alaska Air's improving interisland profitability and sees upside ahead related to synergies from the acquisition of Hawaiian Airlines.&nbsp;
DAL: Goldman Sachs resumed coverage of Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) as a Buy with an $83 price target, representing 28% upside to the stock's current levels. The firm said its Buy rating is underpinned by Delta's growth in loyalty revenue, which is driven partly by its long-term credit card agreement with American Express. 
O&#8217;Brien also highlighted the airline's exposure to passenger demand for premium services and its competitors exiting key cities where Delta continues to operate.&nbsp;
UAL: O&#8217;Brien forecasted United Airlines Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NYSE">UAL</a>) to end 2024 with margins at nearly pre-pandemic levels and noted this as the highest rate of recovery among the firm's airline coverage. The Goldman Sachs analyst also highlighted United as among the best positioned to serve the increasing premium and corporate consumer demand.&nbsp;
Goldman Sachs resumed coverage on United Airlines with a Buy rating and a $119 price target, representing 31% upside to the stock's current level.&nbsp;
JBLU: The firm resumed coverage on shares of JetBlue Airways Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) with a Sell rating and a $5.50 price target. O'Brien pointed to capacity restraints resulting from aircraft grounded for required maintenance and air traffic control staffing shortages in New York City, where the airline has a large hub. The analyst said that both issues are out of management's control and expects both to continue through the short term.&nbsp;
LUV: The Goldman Sachs analyst resumed coverage on Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) shares with a Sell rating and announced a $28 price target. O'Brien said Southwest's product <a href="https://www.benzinga.com/insights/analyst-ratings/24/11/42004766/beyond-the-numbers-9-analysts-discuss-southwest-airlines-stock">and network</a> are not aligned with the increasing demand for premium air services, putting it at a disadvantage in the current market.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/42009316/jeff-bezos-ex-wife-mackenzie-scott-sells-more-amazon-shares">Jeff Bezos&#8217; Ex-Wife MacKenzie Scott Sells More Amazon Shares</a></li>
</ul>
Image: VanderWolf from Shutterstock

Analyst Color

Price Target

Travel

Analyst Ratings

General

JBLU

Delta, United, Alaska Air Are Top Analyst Picks In Airline Sector

Scotiabank analyst Robert Hope maintains Tidewater Midstream (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TWM#TSX">TWM</a>) with a Sector Perform and lowers the price target from C$0.45 to C$0.3.

TSX:TWM

Scotiabank Maintains Sector Perform on Tidewater Midstream, Lowers Price Target to C$0.3

RBC Capital analyst Ben Hendrix maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Outperform and lowers the price target from $68 to $58.

RBC Capital Maintains Outperform on CVS Health, Lowers Price Target to $58

The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) Board of Directors today announced that it has elected Tim Buckley as its newest member, effective January 1, 2025. Buckley will serve on the Finance and Governance &amp; Public Policy committees.
Buckley, 55, previously served as Chair and CEO of The Vanguard Group, where he successfully led one of the largest investment management firms in the world, with nearly $10 trillion in assets under management.

Management

Boeing Elects Tim Buckley To Board Of Directors, Effective January 1, 2025. Buckley Will Serve On The Finance And Governance & Public Policy Committees

<ul>
<li>Advances LiDAR technology for improved contrail analysis</li>
<li>Provides insights for development of new aircraft engines</li>
<li>Industry actively collaborating to understand contrail science with aim to reduce emissions</li>
</ul>
CINCINNATI, Nov. 15, 2024 /PRNewswire/ -- GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) and NASA are partnering on a series of unique flight tests to help further the aviation industry's understanding of contrails, using new test methods and technologies.
Contrails are clouds made of ice particles, which can be created when airplanes fly through cold, humid air. Persistent contrails are estimated to have a warming climate impact. Flight tests will support industry research efforts to better understand contrail science and enable new technology development that can reduce non-CO2 emissions.
Flights for the Contrail Optical Depth Experiment (CODEX) will be conducted the week of November 18 from Virginia. NASA Langley Research Center's G-III aircraft will follow GE Aerospace's Flying Test Bed in the sky and scan the aircraft wake with Light Detection and Ranging (LiDAR) technology. This will advance the use of LiDAR by NASA to generate three-dimensional imaging of contrails to better characterize how contrails form and how they behave over time.
For GE Aerospace, this represents new operating methods for its 747 Flying Test Bed, expanding capabilities ahead of flight tests planned this decade to evaluate performance of new commercial engine technologies. Open Fan, advanced combustion designs, and other propulsion systems are being developed through CFM International's Revolutionary Innovation for Sustainable Engines (RISE)&#x2A; program.

GE Aerospace And NASA Partnering On Flight Tests To Accelerate Industry's Understanding Of Contrails; Advances LiDAR Technology For Improved Contrail Analysis; Provides Insights For Development Of New Aircraft Engines

Macro Economic Events

WIIM

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower amid weakness in chip and pharma stocks and as investors assess president-elect Trump's nominees.

Scotiabank analyst Meny Grauman maintains Sagicor Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SFC#TSX">SFC</a>) with a Sector Outperform and raises the price target from C$9 to C$10.

TSX:SFC

Scotiabank Maintains Sector Outperform on Sagicor Financial, Raises Price Target to C$10

Scotiabank analyst Mario Saric maintains H&amp;R REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HR#TSX">HR</a>) with a Sector Perform and raises the price target from C$11.5 to C$11.75.

TSX:HR

TSX:HR/UN

Scotiabank Maintains Sector Perform on H&R REIT, Raises Price Target to C$11.75

Cannabis producer Rubicon Organics Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/ROMJ#TSXV">ROMJ</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ROMJF#OTCQX">ROMJF</a>) reported its third quarter financial results for the three months ended Sept. 30, 2024.
The British Columbia-based company achieved a record net revenue of CA$13.5 million ($9.6 million) for the quarter, representing a 34% increase year-over-year.
"Rubicon Organics continues to innovate and expand our product offerings, solidifying a strong market share in premium flower, pre-rolls, edibles, and more," said CFO Janis Risbin. "I'm particularly proud of the success of our 2024 vape launch, which has already achieved 55% distribution in just six months. Looking ahead, we expect to drive further growth in Canada and beyond, as we intend for new market entry in 2025."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40397166/rubicons-revenue-grows-profit-margins-shrink-in-q2-whats-next-for-this-canadian-cannabis-company">Rubicon&#8217;s Revenue Grows, Profit Margins Shrink In Q2– What&#8217;s Next For This Canadian Cannabis Company?</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Q3 2024 Financial Highlights</h3>
<ul>
<li>Net revenue totaled CA$13.5 million, representing a 34% increase year-over-year.</li>
<li>Gross profit before fair value adjustments was CA$4.4 million, representing a 35% year-over-year increase.</li>
<li>Adjusted EBITDA came in positive at CA$2 million, up from CA$1.1 million in the prior year's period.</li>
<li>Positive operating cash flow was CA$0.9 million.</li>
</ul>
<h3 class="wp-block-heading">Product And Brand Highlights</h3>
<ul>
<li>Wildflower is one of Canada&#8217;s leading cannabis wellness brands, with a 27.8% market share in topicals.</li>
<li>The company's premium edibles held a 28.5% market share in the third quarter of 2024.</li>
<li>Rubicon launched 1964 Supply Co vape products, with strong growth and distribution already at 55% in six months.</li>
</ul>
<h3 class="wp-block-heading">ROMJF Price Action</h3>
Rubicon's shares traded 2.5263% lower at $0.2778 per share at the time of writing on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/05/38871730/canadian-marijuana-company-rubicon-organics-reports-flat-revenue-adjusted-ebitda-loss-provides-p">Canadian Marijuana Company Rubicon Organics Reports Flat Revenue, Adjusted EBITDA Loss, Provides Positive Outlook</a></li>
</ul>

Cannabis

Earnings

ROMJF

TSX:ROMJ

TSXV:ROMJ

Canadian Cannabis Producer Rubicon Reports Record Q3 Revenue Of $13.5M, 34% YoY Growth

Morgan Stanley analyst Chris Snyder maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Overweight and raises the price target from $320 to $335.

Morgan Stanley Maintains Overweight on Rockwell Automation, Raises Price Target to $335

Morgan Stanley analyst Benjamin Swinburne maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Overweight and raises the price target from $110 to $125.

Morgan Stanley Maintains Overweight on Walt Disney, Raises Price Target to $125

Scotiabank analyst Phil Hardie maintains CI Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CIX#TSX">CIX</a>) with a Sector Perform and raises the price target from C$25 to C$26.

TSX:CIX

Scotiabank Maintains Sector Perform on CI Financial, Raises Price Target to C$26

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/11/2024-11-15_08h38_46.png" alt="" style="width:624px" /></figure>
<h3 class="wp-block-heading">Powell Speaks The Truth</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-powell-speech-trump-appointments-spy-mc-11152024">click here</a> for an enlarged chart of SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which represents the benchmark stock market index S&amp;P 500 (SPX).
Note the following:
<ul>
<li>It is worth a reminder that The Arora Report is politically agnostic.&nbsp; Our sole job is to help our members extract the maximum amount of money out of the markets with the least possible risk.</li>
<li>The price action on the chart shows that the rip roaring Trump rally is taking a breather.</li>
<li>The chart shows that the stock market is still above the breakout line.</li>
<li>RSI on the chart shows that the stock market has pulled back, reflecting a loss of momentum. The stock market is still overbought.</li>
<li>The chart shows that the volume remains low.&nbsp; This indicates that institutional investors are not rushing to buy stocks.</li>
<li>Yesterday, Powell spoke that truth – the market did not like it.&nbsp; Powell said, "The economy is not sending any signals that we need to be in a hurry to lower rates."&nbsp; Powell elaborated, "The strength we are currently seeing in the economy gives us the ability to approach our decisions carefully."</li>
<li>Powell's remarks brought some selling into stocks and bonds.</li>
<li>This morning, in the early trade, selling continues.</li>
<li>The reason for some selling is that the prevailing wisdom on Wall Street has been that another rate cut in December was a sure thing.&nbsp; The Arora Report has been questioning Wall Street's wisdom and sharing with you that the data does not support another rate cut.</li>
<li>Some conservative commentators are upset believing that the reason Powell started rate cuts with a 50 bps cut was to help Kamala Harris get elected.&nbsp; Now that Trump has been elected, Powell is in no hurry to cut rates.</li>
<li>In The Arora Report analysis, even though the data does not support a rate cut in December, Powell is going to feel pressure from Trump and Republicans to cut rates.&nbsp; There is also a significant amount of data between now and the December Fed meeting.</li>
<li>In The Arora Report analysis, based on a 360 degree view, including the political pressure and the pressure from Wall Street to cut rates, the probability of a rate cut in December is now about 60%.&nbsp;&nbsp;</li>
<li>There is consternation about several Trump picks.&nbsp; Impacting the market most are Trump's picks of RKF Jr, Matt Gaetz, and Pete Hegseth.&nbsp; These picks are bringing selling in vaccine makers such as Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), BioNTech SE ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).&nbsp; There is also selling in other healthcare stocks, including weight loss drug companies Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and packaged food stocks such as The Kraft Heinz Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>).&nbsp; There is also selling in defense stocks such as Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), Northrop Grumman Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>), and Rtx Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>).&nbsp; There is also selling in big tech stocks.</li>
<li>The latest economic data is strong.&nbsp; The U.S. economy is about 70% consumer based.&nbsp; For this reason, prudent investors pay attention to retail sales.&nbsp; Here are the details of the just released data:
<ul>
<li>Retail sales came at 0.4% vs. 0.3% consensus.</li>
<li>Retail sales ex-auto came at 0.1% vs. 0.2% consensus.</li>
</ul>
</li>
<li>There are hundreds of indicators.&nbsp; At The Arora Report, the system has been refined through decades of research to share with you only those indicators that matter.&nbsp; Normally, we do not mention the NY Fed Empire State Manufacturing Index.&nbsp; Today, we are mentioning it due to its exceptional strength.&nbsp; The index came at 31.2 vs. 3.3 consensus.&nbsp; This indicates that manufacturing in the New York area has picked up steam. &nbsp; If similar strength is happening in the rest of the country, that would argue against further cutting interest rates. The problem for investors is that stock valuations are so high that to sustain them, rate cuts are needed.&nbsp;&nbsp;</li>
</ul>
<h3 class="wp-block-heading">Magnificent Seven Money Flows</h3>
In the early trade, money flows are positive in Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In the early trade, money flows are negative in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
In the early trade, money flows are negative in S&amp;P 500 ETF (SPY) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h3 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h3>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).  The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).  The most popular ETF for oil is United States Oil ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>).
<h3 class="wp-block-heading">Bitcoin</h3>
Even the slightest dips in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) are being bought.
<h3 class="wp-block-heading">Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h3 class="wp-block-heading">Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Politics

Federal Reserve

AAPL

AMZN

BNTX

GOOG

MRNA

MSFT

NVAX

NVDA

TSLA

Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth

<a href="https://en.yna.co.kr/view/AEN20241116000500315?section=national/diplomacy">https://en.yna.co.kr/view/AEN20241116000500315?section=national/diplomacy</a>
&nbsp;
President Yoon Suk Yeol and Chinese President Xi Jinping held their first talks in two years in Peru on the sidelines of the Asia-Pacific Economic Cooperation (APEC) summit to discuss bilateral ties and regional issues.
The two leaders are expected to discuss various measures to facilitate economic cooperation, culture and people-to-people exchanges and share in-depth opinions on regional security, according to Yoon's office.
Among likely agenda items is North Korea's troop deployment to Russia in support of its war in Ukraine, which has caused concerns over broader security implications on the Korean Peninsula.
In an interview with Spanish news agency EFE on Thursday, Yoon said Seoul will continue maintaining "strategic dialogue" with China to encourage it to play a role in promoting regional stability.
Amid a deepening military alignment between Pyongyang and Moscow, Beijing recently included South Korea on the list of temporary visa waiver countries. Seoul welcomed the move, voicing hope that it will help further promote "friendly sentiment" between the two neighbors.

'South Korea's Yoon Tells China's Xi The Two Countries Need To Cooperate For Peace In The Face Of North Korea, Russia Military Cooperation' - Yonhap

FuboTV's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) short percent of float has fallen 10.5% since its last report. The company recently reported that it has 34.91 million shares sold short, which is 10.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.59 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>FuboTV Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731690923_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for FuboTV has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing FuboTV's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, FuboTV's peer group average for short interest as a percentage of float is 4.68%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

FUBO

Looking Into FuboTV's Recent Short Interest

UnitedHealth Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) short percent of float has fallen 8.33% since its last report. The company recently reported that it has 7.06 million shares sold short, which is 0.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>UnitedHealth Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731690918_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UnitedHealth Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing UnitedHealth Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, UnitedHealth Group's peer group average for short interest as a percentage of float is 4.90%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(UNH) - Analyzing UnitedHealth Group's Short Interest

According to Circana, a market research company, sales of ultra-large TVs – 97 inches and bigger – have gone up by 877% in the last year, while prices have dropped by 53%.&nbsp;
More than 70% of Best Buy&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) stores in the United States now feature these ultra-large TVs, making it simpler to see and buy them. XXL TVs are also available at retailers like Target, Walmart and Costco.
Don't Miss:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before closing date.</a></li>
</ul>
The popularity of these big TVs is due to better technology, cheaper production and more consumer interest. As CNN reports, during the pandemic, many people bought 65-inch TVs to make staying at home more fun and now, a few years later, many are ready to upgrade to even bigger screens.
Price is one of the biggest drivers of this behavior. A year ago, 98-inch TVs were seen as <a href="https://www.benzinga.com/news/24/01/36575301/this-massive-137-inch-foldable-tv-is-futuristic-luxurious-and-out-of-most-peoples-reach">luxury items</a>, but now they are available for prices between $1,699 and $2,999 and many stores offer free delivery and installation. Prices for TVs between 75 and 96 inches have also come down, though not as much – they are down by about 6%, with sales increasing by 19%. Meanwhile, XXL TVs are becoming more common.
With more price options, it&#8217;s easier for people to invest in a home theater-like experience.&nbsp;
Trending: The global games market is projected to generate $272B by the end of the year –<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
The appeal of XXL TVs is not just because of their size; it's also about their features. Brands like Samsung (OTCPK: SSNLF) and LG have added new technology, like multi-view modes, which let you split the screen into four parts to watch different things at the same time. This is fantastic for sports enthusiasts who like to follow several games. Some TVs also use AI to enhance picture quality, which results in a more enjoyable viewing experience.
However, the appeal of XXL TVs isn't just for movies and sports but also <a href="https://www.benzinga.com/news/24/01/36594962/netflix-games-download-surge-by-180-signaling-success-in-gaming-expansion">for gamers</a> because these big screens have features like low input lag, high refresh rates and support for the latest gaming consoles. Better sound quality, with features like Dolby Atmos, makes the experience more enjoyable and immersive.
If you're unsure if these big TVs will fit in your living room, tools like Best Buy's AR Viewer can help you see how a 97-inch TV will look in your space before buying it.
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a>
The rise in XXL TV sales has boosted the industry, which has had some struggles recently. With higher costs due to inflation, people have been more careful about spending money on big purchases. Nevertheless, Corie Barry, the CEO of Best Buy, stated that when customers realize the advantages, they are still prepared to spend money on expensive goods. With their more affordable costs and superior features, XXL TVs appear to be a good fit.
Paul Gagnon, from consumer research firm Circana, noted that this trend is similar to what happened a few years ago with 65-inch TVs: People upgraded for a better viewing experience and now they're upgrading again for even larger screens. This trend toward bigger TVs is expected to continue through 2025, as more people replace their pandemic-era TVs with newer, larger models.
If you are considering an upgrade, now seems like a good time. Prices are dropping, features are improving and XXL TVs are easier to find. The trend toward bigger screens will continue, creating better home entertainment options.
Read Next:
<ul>
<li>With over 7.8K investors including Meta, Google and Amazon Execs – this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in 2 weeks.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

SSNLF

Shopping Spree – Sales Of Ultra-Large XXL TVs Have Skyrocketed 877% As Prices Drop By 53% In The Past Year

CrowdStrike Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NYSE">CRWD</a>) short percent of float has fallen 10.03% since its last report. The company recently reported that it has 8.04 million shares sold short, which is 3.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.56 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>CrowdStrike Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731690912_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CrowdStrike Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing CrowdStrike Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, CrowdStrike Holdings's peer group average for short interest as a percentage of float is 5.07%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CRWD

Looking Into CrowdStrike Holdings's Recent Short Interest

Scotiabank analyst Mario Saric maintains Brookfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>) with a Sector Outperform and raises the price target from $65 to $69.

Scotiabank Maintains Sector Outperform on Brookfield, Raises Price Target to $69

EF Hutton initiated coverage of ImmunityBio (IBRX) with a Buy rating and $30 price target ImmunityBio is a late-stage clinical biotechnology compan...

ImmunityBio initiated with a Buy at EF Hutton

Immunotherapy innovator ImmunityBio (IBRX) announced that the first patients have been dosed in an initial trial studying the potential of the comp...

ImmunityBio:  1st patient dosed in CAR-NK cell therapy study relapsed NHL

ImmunityBio extends gains after trial update

ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful

ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025

Unusual total active option classes on open include: Hawaiian Electric (HE), PureCycle Technologies (PCT), Rumble (RUM), ON Semiconductor (ON), Imm...

Unusually active option classes on open October 28th

Biotech ImmunityBio ($IBRX) has grabbed investors' attention. Its stock has shot up over 77% in the past few days on news of the first patients bei...

ImmunityBio's (IBRX) Plans to Bridge Gaps in Cancer Treatments, Stock Soars

ImmunityBio Non-GAAP EPS of -$0.14 beats by $0.04, revenue of $6.1M beats by $3.18M

Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on ImmunityBio (IBRX – Research Report) today and set a price target of $4.75. The ...

Piper Sandler Keeps Their Hold Rating on ImmunityBio (IBRX)

Immunitybio Inc ( ($IBRX) ) has released its Q3 earnings. Here is a breakdown of the information Immunitybio Inc presented to its investors. Immuni...

ImmunityBio Inc. Reports Earnings Amid Financial Challenges

BMYMP

RILY

Press Releases

IMMUNITYBIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

ImmunityBio's ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

IMMUNITYBIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX

ImmunityBio to Participate in the Jefferies London Healthcare Conference

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio's CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

Legal

IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

ImmunityBio Reports Third-Quarter 2024 Financial Results

Small Cap

Opinion

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

IOVA

ONCY

SNDX

SWTX

TSX:ONC

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

ADMA Biologics

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Alkermes

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BridgeBio Pharma

Biohaven

Denali Therapeutics

Dyne Therapeutics

Amicus Therapeutics

Immunovant

Janux Therapeutics

Kymera Therapeutics

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

PTC Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Veracyte

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

D. Boral Capital

EF Hutton

Piper Sandler

Jefferies

이들 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)의 주식은 회사가 재발성 <a href="https://www.benzinga.com//node/41516867" target="_blank" rel="noreferrer noopener">B-세포 비호지킨 림프종</a>에 대한 CAR-NK 세포 치료제의 1상 임상 연구에서 첫 환자에게 투여했다고 발표한 후 49.86% 상승했다.
2. 스트라이드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>)의 주식은 회사가 1분기 실적이 예상보다 좋게 나타났고, 2025 회계연도 및 2분기 <a href="https://www.benzinga.com//node/41487340" target="_blank" rel="noreferrer noopener">매출 가이던스도 예상치를 상회</a>했다고 발표한 후 41.43% 급등했다. 애널리스트들이 <a href="https://www.benzinga.com/quote/lrn/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표</a>를 올렸다.
3. 퓨어사이클 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>)의 <a href="https://www.benzinga.com//node/41409452" target="_blank" rel="noreferrer noopener">주식은 32.21% 상승</a>했다.
4. 트럼프 미디어 앤 테크놀로지 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)의 주식은 지난주에 31.68% 상승했다. 이 주식은 다가오는 미국 선거를 앞두고 변동성을 보였다.
5. 지커 인텔리전트 테크놀러지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>)의 주식은 29.31% 상승했다. 여러 미국 상장 중국 주식들이 인민은행이 <a href="https://www.benzinga.com//node/41547149" target="_blank" rel="noreferrer noopener">7,000억 위안</a> (약 983억 6천만 달러)를 은행 시스템에 주입하고 금리를 2.0%로 유지했다고 발표한 후 상승했다.
6. 아이온큐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>)의 주식은 27.52% 상승했다.
7. 허크 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>)의 주식은 회사가 3분기 매출 실적이 예상보다 좋았고 2024 회계연도 장비 <a href="https://www.benzinga.com//node/41455862" target="_blank" rel="noreferrer noopener">임대 매출 성장 전망을 상향 조정</a>했다고 발표한 후 21.76% 상승했다.
8. 테라울프(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>)의 주식은 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 가격 상승으로 18.59% 상승했다. 이 회사는 또한 4억 2,500만 달러를 전환사채로 조달할 것을 제안했다.
9. 아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41462205" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">지오(Zio) AT 기기</a>의 이전 설계 변경과 관련된 510(k) 제출에 대해 FDA 승인을 받았다고 발표한 후 주가가 20.76% 상승했다.
10. 셀레스티카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>)의 주식은 회사가 3분기 실적이 예상보다 좋았고 4분기 매출 가이던스를 예상치를 상회한다고 발표한 후 19.99% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/41523564" target="_blank" rel="noreferrer noopener">주가 목표</a>를 올렸다.
또한 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%85%8C%EC%8A%AC%EB%9D%BC%EC%99%80-%EB%A6%AC-%EC%98%A4%ED%86%A0%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10%EA%B0%9C-%EB%8C%80/" target="_blank" rel="noopener">테슬라와 리 오토는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 21일-10월 25일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%A0%9C%EB%89%B4%EC%9D%B8-%ED%8C%8C%EC%B8%A0-%EB%B0%8F-%ED%83%91%EB%B9%8C%EB%93%9C%EA%B0%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%9D%B8-10/" target="_blank" rel="noopener">제뉴인 파츠 및 탑빌드가 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 21일-10월 25일)</a></li>
</ul>
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 중형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>빌리빌리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>)의 주가는 지난주 &#8216;산구오: 무딩티엔샤(San Guo: Mou Ding Tian Xia)&#8217; 발표 이후 23.32% 상승했다. 또한 JP모건 애널리스트 다니엘 첸(Daniel Chen)은 중국의 빌리빌리를 중립에서 비중확대로 상향 조정하고 <a href="https://www.benzinga.com//node/39418621" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">21</a>달러 가격 목표를 발표했다.</li>
<li>이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)의 주가는 안크티바(ANKTIVA)가 여러 주에 걸쳐 <a href="https://www.benzinga.com//node/39417764" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">첫 번째 상용 투여량</a>을 투여한 보험 적용 범위를 발표한 이후 지속적인 강세로 22.36% 상승했다.</li>
<li>사솔(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>)은 회사가 법원에서 회사와 토탈에너지스 SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) 마켓팅에 유리한 판결을 내렸다고 발표한 후 주가는 20.89% 상승했다. 또한 손해배상금으로 38.9억 랜드, <a href="https://www.benzinga.com//node/39412202" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">이자로 약 2,300만 랜드</a>를 받았다.</li>
<li>지난주 올리즈 바겐 아울렛 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>)의 주식은 JP모건이 중립에서 <a href="https://www.benzinga.com/quote/OLLI/analyst-ratings">비중확대</a>로 평가를 올린 이후 15.25% 상승했다.</li>
<li>인트라-셀룰러 테라피스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)는 회사가 루마테페론을 주요 우울 장애 환자를 위한 보조 요법으로 평가하고 <a href="https://www.benzinga.com//node/39382029" target="_blank" rel="noreferrer noopener">1차 및 주요 2차 평가변수를 충족</a>시키는 두 번째 3상 시험의 톱라인 결과를 발표한 후 주가는 13.18% 상승했다.      shares advanced 12.06% on overall strength in chip stocks. Also, B. Riley Securities analyst <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">raised the price forecast</a> on the stock from $45 to $50.</li>
<li>앰코 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>)는 전반적인 칩주 강세로 주가는 12.06% 상승했다. 또한 B. 라일리 증권(B. Riley Securities)의 분석가는 주식 가격 <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">예측</a>을 45달러에서 50달러로 높였다.</li>
<li>아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>)는 회사가 이전에 공개한 <a href="https://www.benzinga.com//node/39411935" target="_blank" rel="noreferrer noopener">제조 자동화 계획</a>의 초기 단계를 시작한 후 기업의 이정표에 도달했다고 발표한 후 주가는 11.53% 증가했다.</li>
<li>로켓 랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)는 주가는 <a href="https://www.benzinga.com//node/39429411" target="_blank" rel="noreferrer noopener">일본 기업 신스펙티브(Synspective)</a>와 도쿄에서 10개 제품 출시 계약을 체결한 후 11.32% 상승했다.</li>
<li>브레드 파이낸셜 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>)는 에버코어 ISI 그룹(Evercore ISI Group)이 이 주식을 언더퍼폼(Underperform)에서 인-라인(In-Line)으로 평가를 올리고 목표 주가를 42달러에서 45달러로 <a href="https://www.benzinga.com/quote/BFH/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정한 </a>이후 10.81% 상승했다. 또한 또한 RBC 캐피털은 해당 주식에 대해 섹터 퍼폼(Sector Perform) 등급을 유지하고 목표 주가를 38달러에서 45달러로 높였다.</li>
<li>BRF S.A.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRFS#NYSE">BRFS</a>)의 주식은 10.69% 상승했다.</li>
</ol>
위키미디어 커먼즈를 통한 사진
기사 읽기: <a href="https://kr.benzinga.com/news/%ea%b2%8c%ec%9e%84%ec%8a%a4%ed%83%91%ea%b3%bc-%ec%9e%90%eb%b9%8c%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%ea%b0%9c%ec%9d%98/" target="_blank" rel="noopener">게임스탑과 자빌은 지난주 최악의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)</a>

Comments

ImmunityBio

뉴스

에 대한 최신 뉴스 ImmunityBio (NASDAQ:IBRX) 주식

월요일, 10월 28, 2024

월요일, 6월 24, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌